




Investor Fact Sheet

First half-year 2023/24


(Unaudited Swiss GAAP FER figures)
in thousand CHF

	Half-year 2023/24	in %	Half-year 2022/23	in %	Change	in %
Sales of goods and services group	255 390	100.0 %	244 244	100.0 %	11 145	4.6 %
thereof continued business group	255 390		205 856		49 534	24.1 %
Ypsomed Delivery Systems	176 527	69.1 %	143 728	58.8 %	32 799	22.8 %
Ypsomed Diabetes Care	72 585	28.4 %	92 013	37.7 %	–19 428	–21.1 %
thereof continued business YDC	72 585		53 625		18 960	35.4 %
Others	6 278	2.5 %	8 504	3.5 %	–2 226	–26.2 %
Gross profit	87 817	34.4 %	65 448	26.8 %	22 370	34.2 %
Operating profit	39 888	15.6 %	19 445	8.0 %	20 442	105.1 %
thereof continued business group	39 888	15.6 %	16 611	6.8 %	23 276	140.1 %
Financial income	2 595	1.0 %	2 341	1.0 %	253	10.8 %
Financial expenses	–4 219	–1.7 %	–5 048	–2.1 %	829	–16.4 %
Income taxes	–1 684	–0.7 %	–1 300	–0.5 %	–384	29.5 %
Net profit	36 579	14.3 %	15 439	6.3 %	21 141	136.9 %
Earnings per share in CHF	2.68		1.17		1.51	129.5 %
Operating profit	39 888	15.6 %	19 445	8.0 %	20 442	105.1 %
Depreciation and impairment of fixed assets	20 541		19 865		676	3.4 %
Amortisation and impairment of intangible assets	15 403		17 573		–2 170	–12.3 %
EBITDA (operating profit before depreciation and amortisation)	75 832	29.7 %	56 883	23.3 %	18 948	33.3 %
Equity ratio in %	61.2 %		65.2 % ¹		–4.0 %	
Investments in fixed assets	51 137		54 645		–3 508	–6.4 %
Investments in intangible assets	39 500		28 310		11 190	39.5 %
Number of employees	2 231		2 059 ¹		172	8.4 %
Number of full-time positions	2 143		1 978 ¹		164	8.3 %

Turnover at group level



EBIT at group level



¹ As per 31 March 2023.

² DiaExpert GmbH divested as per 31 December 2022.

Further information on significant shareholders and shareholder groups as well as other financial figures of the Ypsomed Group are available in the Semiannual Report 2023/24 and on www.ypsomed.ch.

mylife Diabetes Care

With its mylife™ Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed's subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).

mylife™ product portfolio (selection)



Delivery Systems

Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world's largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.

Drugs are becoming more specific, e.g. in the treatment of autoimmune diseases. Instead of a generic drug (e.g. Humira®), a large number of new, very specific drugs come onto the market. New drugs for Alzheimer's disease, obesity and rare diseases are being developed. Cancer drugs are also becoming more specific. Efforts to develop active ingredients for subcutaneous injection open up opportunities for self-medication with auto- and patch injectors.

YDS product portfolio (selection)



Legal disclaimer: The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG, its advisors or representatives, nor their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as "may", "plans", "expects", "believes" and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.

Ypsomed Holding AG

Thomas Kutt, Head Investor Relations // Brunnmattstrasse 6 // 3401 Burgdorf // +41 34 424 35 55 // thomas.kutt@ypsomed.com // www.ypsomed.ch

YPSOMED
SELF CARE SOLUTIONS